Nigrostriatal Lesions Alter Oral Dyskinesia and c-Fos Expression Induced by the Serotonin Agonist 1-(m-Chlorophenyl)piperazine in Adult Rats

Philippe De Deurwaerdère and Marie-Françoise Chesselet
Department of Neurology, University of California, Los Angeles School of Medicine, Los Angeles, California 90095

The loss of dopaminergic innervation of the basal ganglia, a group of subcortical regions involved in motor control, is the hallmark of Parkinson’s disease. The resulting molecular and cellular alterations mediate behavioral deficits and may modify neuronal responses to other neurotransmitters. In the present study, we sought to determine the effects of chronic dopamine (DA) depletion on responses mediated by stimulation of serotonergic 2C (5-HT<sub>2C</sub>) receptors, a serotonergic receptor subtype present in discrete regions of the basal ganglia. Specifically, the effects of unilateral lesions of nigrostriatal DA neurons on oral dyskinesia and Fos protein expression induced by the non-selective 5-HT<sub>2C</sub> agonist 1-(m-chlorophenyl)piperazine (m-CPP) were examined.

Confirming previous findings, both peripheral and local injections of m-CPP into the subthalamic nucleus elicited oral dyskinesia. Nigrostriatal lesions markedly enhanced oral bouts induced by peripheral but not intrasubthalamic administration of m-CPP. In intact rats, Fos expression was increased by m-CPP (1 mg/kg, i.p.) in the striatum and the subthalamic nucleus. After nigrostriatal lesions, m-CPP-induced Fos expression remained unchanged in the subthalamic nucleus but was reduced in the medial quadrants of the striatum and was markedly enhanced in the entopeduncular nucleus. These data demonstrate regionally specific alterations in behavioral and cellular responses to a serotonergic agonist in an animal model of Parkinson’s disease.

Key words: Parkinson’s disease; dyskinesia; dopamine; serotonin; basal ganglia; serotonin 2C receptors; c-Fos; m-CPP

Parkinson’s disease is characterized by the progressive loss of nigrostriatal dopaminergic neurons. Numerous studies have demonstrated long-term consequences of dopamine (DA) depletion on GABAergic and glutamatergic functions in the basal ganglia (Chesselet, 2000). However, much less is known about the effects of nigrostriatal lesions on serotonergic function.

Serotonergic neurons innervate all regions of the basal ganglia and act on several receptor subtypes (Azmitia and Segal, 1978; Barnes and Sharp, 1999). Serotonergic 2C (5-HT<sub>2C</sub>) receptors are of particular interest because they are known to mediate oral dyskinesia (Stewart et al., 1989; Gong et al., 1992; Eberle-Wang et al., 1996), a side effect of prolonged administration of either dopamine antagonists or 1,3,4-dihydroxyphenylalanine (l-DOPA), the main treatment of Parkinson’s disease (Tarsy and Baldessarini, 1984; Chase et al., 1994; Ebabi and Srinivasan, 1995). Indeed preclinical and clinical studies suggest that increased serotonin (5-HT<sup>+</sup>) transmission plays a role in dyskinesia (Meltzer and Nash, 1991; Melamed et al., 1996) and that drug acting at 5-HT<sub>2C</sub> receptors may be useful in Parkinson’s disease and schizophrenia (Roth et al., 1992; Ikeguchi and Kuroda, 1995; Fox et al., 1998).

5-HT<sub>2C</sub> receptors are present in the striatum, the substantia nigra pars reticulata (SNr), the internal segment of the globus pallidus (GP) [entopeduncular nucleus (EPN) in rats], and the subthalamic nucleus (Pazos et al., 1985; Eberle-Wang et al., 1997; Pasqualetti et al., 1999; Clemett et al., 2000). Evidence indicates that 5-HT<sub>2C</sub> receptors contribute to the regulation of dopaminergic neurons (Trent and Tepper, 1991; De Deurwaerdère and Spampinato, 1999). However, dopaminergic neurons do not express 5-HT<sub>2C</sub> receptor mRNA (Eberle-Wang et al., 1997; Pasqualetti et al., 1999), suggesting that this effect is indirect. In contrast, electrophysiological, biochemical, and behavioral data showed a direct influence of 5-HT<sub>2C</sub> receptors on GABAergic neurons of the striatum and the substantia nigra pars reticulata (El Mansari et al., 1994; Rick et al., 1995; Fox et al., 1998) and on glutamatergic neurons of the subthalamic nucleus (Eberle-Wang et al., 1996).

To understand the functional consequences of the loss of dopaminergic neurons, as occurs in Parkinson’s disease, it is important to elucidate how chronic alterations in dopamine levels alter neuronal responses to remaining neurotransmitters. Behavioral experiments have revealed that lesions of dopaminergic neurons in neonates dramatically increase the response to the nonselective 5-HT<sub>2C</sub> agonist 1-(m-chlorophenyl)piperazine (m-CPP) in adult rats (Gong and Kostrzewa, 1992). However, it is unclear whether this potentiation is the consequence of a supersensitivity to 5-HT agonists occurring only in rats with a neonatal lesion (El Mansari et al., 1994; Kostrzewa et al., 1998) or whether behavioral or cellular responses to m-CPP are also altered by nigrostriatal lesions in adults.

In the present study, we sought to determine whether a unilateral lesion of the nigrostriatal dopaminergic pathway in adult rats, a model of Parkinson’s disease, alters the ability of m-CPP to (1) induce oral movements in rats and (2) induce the expression of...
Fos protein, the product of the immediate early gene c-fos, a tool for exploring neuronal responses in discrete brain regions.

**MATERIALS AND METHODS**

**Surgeries.** All procedures were performed on male Sprague Dawley rats (Charles River Laboratories, Los Angeles, CA) in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the local animal care committee. Before any surgery, rats (250–275 gm) were maintained on a 12 h light/dark schedule with food and water available ad libitum.

Lesions of the dopaminergic neurons located in the substantia nigra pars compacta (SNc) were performed as described previously (Delgado et al., 1995). Briefly, rats were anesthetized with equithesin (prepared as per the instruction of Janssen-Saburutby Laboratories, Kansas City, MO) and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). The tip of the injector was stereotaxically implanted in the left substantia nigra pars compacta [anteroposterior (AP), 3.4; lateral (L), 1.8; ventral (V), 2 with respect to interaural zero] (Paxinos and Watson, 1986). Eight micrograms (free base) of 6-hydroxydopamine (6-OHDA) (Sigma, St. Louis, MO), dissolved in 4 μl of NaCl containing 0.1% ascorbic acid, were administered through the cannula over 4.5 min, and the cannula was left in place for 5 min after the injection before being slowly removed. Rats were pretreated 30 min before the 6-OHDA infusion with 25 mg/kg desipramine to protect noradrenergic projections. Rats given “sham” lesions received an injection of desipramine, followed by vehicle only into the substantia nigra.

Three weeks after infusion of 6-OHDA or its vehicle in the SNc, rats were screened for the completeness of the lesion by subcutaneous injection of 0.05 mg/kg apomorphine. Rats with nigrostriatal lesions that did not show at least 100 rotations during 30 min after apomorphine injection were excluded from the study. Sham-lesioned rats also received the apomorphine injection but, as expected, did not show any rotational behavior.

In experiments requiring local infusion into the subthalamic nucleus, rats were anesthetized with equithesin 2 weeks after the intranigral administration of 6-OHDA or its vehicle and placed in a stereotaxic frame. The guide cannula (22 gauge inner diameter; Plastics One Inc., Roanoke, VA) was stereotaxically positioned such that the tip of the injector was located at the following coordinates: AP, 5.1; L, 2; V, 2.1 corresponding to the left subthalamic nucleus relative to the interaural zero (Paxinos and Watson, 1986). The guide shaft was secured to the skull with dental resin (SNAP; Parkell, Farmingdale, NY) and anchored to stainless steel mounting screws placed in the skull. After this surgery, rats were housed individually.

Injectors used during the course of this study were constructed from commercially available dummy and internal cannulas (Plastics One Inc.), as described previously (Parry et al., 1994). Briefly, an injector was prepared by threading a 35 cm piece of fused silica (outer diameter of 150 μm; inner diameter of 73 μm) through a 28 gauge internal cannula such that a 1 mm tip of fused silica extended from the end of the cannula shaft. The fused silica portion of the injector was sheathed up to the internal cannula in polyethylene-20 tubing, and all junctions were secured with epoxy.

**Behavioral testing.** Rats were exposed to the behavioral room conditions before the testing day to facilitate their adaptation to transportation and to the behavioral room. On the day of behavioral testing, each rat was placed in clear circular plastic chambers (12 inches in diameter; 18 inches in height). After a 1 h adaptation period and immediately before the onset of behavioral observations, the 3-HT agonist m-CPP or its vehicle were administered either systemically (intraperitoneally) or locally into the subthalamic nucleus.

Details of the procedure for microinfusion into the subthalamic nucleus have been described in previous reports (Parry et al., 1994). The awake rats were gently handled, and m-CPP or its vehicle were infused directly into the subthalamic nucleus via an injector placed within the surgically implanted guide cannula. A total volume of 0.1 μl was infused over 54 sec. The injector was left in place for an additional 60 sec to allow diffusion of the drug away from the injector tip.

After either type of drug injection, the rats were returned to the testing cage and observed continuously for 60 min for bouts of orofacial movements. The number of oral bouts/60 min was quantified by an observer blind to the drug schedule administration. Oral activity was defined as vacuum chewing, jaw tremors, and tongue darting that occurred without any reference to an evident physical material. Thus, oral activity occurring with feeding, grooming, licking, or sniffling was not counted. Moreover, an interval of 2 sec without oral activity was required to consider the oral bout fully terminated. The duration of each oral bout was not measured (Parry et al., 1994; Eberle-Wang et al., 1996; Mehta et al., 2000).

**Pharmacological treatment.** All experiments assessing the effect of m-CPP on oral movements or on Fos expression started 4.5 weeks after the lesion of DA neurons and were done during the diurnal portion of the day. In the case of systemic injection, rats with sham or 6-OHDA lesions were given only one injection (m-CPP or saline). After the 1 h period of behavioral testing, rats were returned to their cages. Two hours after m-CPP or saline injection, rats were anesthetized and perfused with 4% paraformaldehyde solution (see below) for Fos and tyrosine hydroxylase (TH) immunohistochemistry.

In the case of local administration of m-CPP into the subthalamic nucleus, doses of m-CPP (0, 0.2, 0.5, and 1 μg/100 nl) were injected in a 5171 subthalamodal order over a 4 week period (1 week interval between injections), such that, at the completion of testing, most rats had received all doses of m-CPP in a random order. Some rats (three of eight rats in each of sham and 6-OHDA-treated groups) lost their head block during the course of the study and, consequently, did not receive all doses. Considering the random design of the pharmacological treatment, results from these rats were included. At the end of the entire experiment, rats were anesthetized and perfused for TH immunohistochemistry experiments and verification of cannula placement into the subthalamic nucleus.

**Immunohistochemistry.** Rats were deeply anesthetized with equithesin and perfused transcardially with 0.1 M PBS, pH 7.4 (at 37°C), followed by ice-cold 4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB). Brains were removed, post-fixed for 2 h in the same fixative, and sunk in 30% sucrose at 4°C. Brains were sectioned on a freezing microtome in approximately –35°C and stored at –80°C. Forebrains were cut at 40 μm on a cryostat (CM1800; Leica, Nussloch, Germany) in the coronal plane. Sections through the striatum, GP, EPN, subthalamic nucleus, and substantia nigra were collected in PBS (0.1 M, pH 7.4), placed in cold cryoprotecting solution containing phosphate buffer (0.05 mM), glycerol (50% v/v), sucrose (40%, and 8%, and 5% v/v), and stored at –24°C pending Fos or TH immunohistochemistry. A Nissl staining was performed on adjacent sections for identification of structures.

After four washes in 0.1 M PB, pH 7.4, at room temperature, sections were incubated in 5% normal goat serum with 0.2% Triton X-100 and then transferred to 1% normal goat serum containing anti-Fos rabbit polyclonal antibody (1:20,000; PC38; Oncogene Science, Cambridge, MA) for 40 hr at 4°C. After six washes in 0.1 M PB (5 min each), sections were incubated during 1 hr in 0.1 M PB containing 1% normal goat serum and biotinylated goat anti-rabbit IgG (1:200; Vector Laboratories, Burlingame, CA). After washes (three times in 0.1 M PB), sections were incubated in avidin-biotin-peroxidase complex (1 hr; Vector Laboratories) for subsequent staining with 3,3’diaminobenzidine (0.05% w/v; Sigma) in 0.1 M PB containing 0.005% H2O2 (Sigma). Sections were incubated during three times this buffer bath until the density of the immunostaining was assessed by omission of the primary or the secondary antibody from the protocol. After processing, tissue sections were mounted onto gelatin-alum-coated slides, dehydrated in ascending concentration of ethanol, and coverslipped with Eukitt mounting medium (Calibrated Instruments, Hawthorne, NY).

For TH immunolabeling, 40-μm-thick midbrain sections were incubated in 5% normal goat serum with 0.3% Triton X-100 in 0.1 M PBS and then transferred to 2% normal goat serum containing anti-TH rabbit polyclonal serum (1:5000; AB151; Chemicon, Temecula, CA) for 72 hr at 4°C. After four washes in 0.1 M PBS (10 min each), sections were incubated during 1 hr in 0.1 M PBS containing 2% normal goat serum and biotinylated goat anti-rabbit IgG (1:200, Vector Laboratories Inc., Burlingame, CA). Subsequent steps were similar to that described above for Fos immunolabeling.

**Verification of cannula placement.** Fifty-micrometer-thick sections were cut through the subthalamic nucleus and stained with cresyl violet for verification of cannula placement within the subthalamic nucleus. Only data from rats in which accurate cannula tract was verified were retained for analysis. Representative tissue sections depicting cannula placement have been published previously (Parry et al., 1994; Eberle-Wang et al., 1996).

**Data analysis.** Before quantitative analysis, sections were viewed at a low magnification, and anatomical regions were outlined based on Nissl staining in serially adjacent sections. Two sections per region were analyzed, except for the SNr in which four sections were analyzed. The
total surface area tissue area examined in this way did not differ between groups and was approximately as follow: subthalamic nucleus, 0.17 mm$^2$; SNr, 0.7 mm$^2$; EPN, 0.25 mm$^2$; GP, 0.3 mm$^2$. As reported previously (Rouillard et al., 1996), the striatum has been analyzed in four quadrants ($\sim 0.5$ mm$^2$ each) corresponding to dorsomedial striatum, ventromedial striatum, dorsolateral striatum, and ventrolateral striatum at the level of the central striatum (approximately AP, 9.2 and 8.8 from interaural level according to the atlas of Paxinos and Watson, 1986). Selected areas were observed under a light microscope (Axioskope 9500) equipped with 20× or 40× bright-field objective. The distribution of immunoreactive cells was examined and counted on each side of the brain. Data in two to four sections per structure were averaged for each rat, and the mean ± SEM of these values were calculated for each group on each side of the brain (six to eight rats per group).

**Drugs.** The neurotransmitter OHDA hydrobromide (Sigma) was prepared in saline containing 0.1% ascorbic acid. The noradrenaline uptake inhibitor desipramine hydrochloride (Sigma) was prepared in injectable water and administered in a volume of 2 ml/kg body weight. m-CPP (Research Biochemicals, Milwaukee, WI) was diluted (calculated as free base) in NaCl 0.9% and injected in a volume of 1 ml/kg body weight in the case of peripheral administration. Apomorphine (Sigma) was dissolved (calculated as free base) in saline containing 0.01% ascorbic acid and injected simultaneously in a volume of 1 ml/kg body weight. The pH of final solutions for all drugs and vehicle was neutral.

**Statistical analysis.** Oral bouts were quantified during each 10 min period for 60 min, and results are expressed as the mean ± SEM. Data were analyzed by a two-way ANOVA, considering the lesion of DA neurons (pretreatment) and m-CPP (treatment) as the main factors. When a significant interaction was found ($p < 0.05$), indicating that the effect of the treatment is modified by the pretreatment, this first statistical analysis was followed by a one-way ANOVA (using group as the main factor), completed by the post hoc Scheffe’s test to allow adequate multiple comparisons between groups. Differences in time course of effect between groups was assessed as described above (two-way ANOVA; 6-OHDA × m-CPP) on each 10 min data point for the 60 min period analysis. A separate one-way ANOVA followed by the post hoc Dunnett’s test was performed to determine the effect of the various doses of m-CPP locally administered into the subthalamic nucleus of sham-lesioned animals.

Results for Fos immunohistochemistry experiments are expressed as the mean ± SEM of immunoreactive cells per square millimeter for each structure. Data obtained in the side ipsilateral and contralateral to the lesion were separately analyzed by a two-way ANOVA (6-OHDA × m-CPP), as described above. A one-way ANOVA was subsequently done to determine whether m-CPP and 6-OHDA lesion affected Fos expression by themselves in the various brain regions examined. All statistical analyses were done with StatView 5.0 (SAS Institute Inc., Cary, NC). In all cases, the threshold for significance was $p < 0.05$.

**RESULTS**

**Lesion of DA neurons**

The extent of the lesion of DA neurons was assessed by (1) turning behavior after injection of apomorphine (0.05 mg/kg, s.c.) and (2) immunolabeling for TH, the rate limiting step of catecholamine synthesis, in midbrain sections. All animals retained for analysis showed >100 turns per 30 min in response to apomorphine. In these animals, immunoreactivity for TH was virtually absent on the side of the lesion along the entire rostrocaudal extent of the substantia nigra (Fig. 1). The loss of neurons in the substantia nigra pars compacta was confirmed histologically with a cresyl violet staining performed on adjacent sections (Delfs et al., 1995). Immunoreactivity for TH in the ventral tegmental area, a region adjacent to the substantia nigra pars compacta that contains dopaminergic cell bodies innervating cortical and limbic regions, was mostly spared by 6-OHDA in our experimental conditions (data not shown).

**Nigrostriatal lesions increase oral movements induced by peripheral administration of m-CPP**

The effect of a unilateral lesion of the nigrostriatal DA pathway on the ability of the nonselective 5-HT$_{2C}$ agonist m-CPP to elicit oral movements is shown in Figure 2. As reported previously, the systemic administration of m-CPP (1 mg/kg, i.p.) stimulated oral bouts during a 1 hr observation period (76.9 ± 3.4 vs 25.1 ± 4.5 in sham-lesioned animals treated with m-CPP and saline, respectively, mean ± SEM, $n = 8$). This effect was markedly increased (+119%) in rats with a 6-OHDA-induced lesion (139.3 ± 5 oral bouts per hour, mean ± SEM, $n = 6$) (two-way ANOVA, treatment × pretreatment, $F_{(3,24)} = 49.9, p < 0.0001$). The lesion did not modify the number of oral movements by itself (25.3 ± 4.8, NS, Scheffe’s test, $n = 6$). Moreover, the lesion of DA neurons did not modify the time course of effect of m-CPP on oral movements. Indeed, the time peak of effect was reached 30 min after the injection of m-CPP in both sham- and 6-OHDA-lesioned rats, and values slowly decreased to almost control values at the end of the experiment (data not shown). Of note, m-CPP did not induce any turning behavior in dopamine-depleted rats.

**Figure 1.** Tyrosine hydroxylase immunoreactivity in the substantia nigra of sham-treated (left) and 6-OHDA-treated (right) rats. Photomicrographs show the absence of dopaminergic neurons on the lesion side in rats treated with 6-OHDA. Dopaminergic neurons are preserved in the ventral tegmental area (VTA). Scale bar, 200 μm.
6-OHDA-treated rats is shown in Figure 3. As reported previously for animals without lesions (Eberle-Wang et al., 1996), m-CPP, locally administered into the nucleus at 0.5, 1, and 0.2 μg/100 nl significantly enhanced the incidence of oral movements (one-way ANOVA, dose as the main factor, $F_{(3,24)} = 11.9, p < 0.0001; n = 6–8$). The maximal effect was obtained after the administration of the lowest dose (74 ± 7.9 oral bouts, mean ± SEM, $p < 0.01$, Dunnett’s test) (Fig. 3). After the injection of 0.5 and 1 μg of m-CPP, the time peak of effect was observed after 30 min, and values returned to saline control levels 50 min after the injection of the drug. In contrast, the effect induced by 0.2 μg of m-CPP was almost stable during the period of measurement and even slightly increased with time (data not shown).

The lesion of dopaminergic neurons did not modify oral movements induced by m-CPP locally administered into the subthalamic nucleus, regardless of the dose administered (two-way ANOVA, treatment × pretreatment, $F_{(2,44)} = 1.78, n = 8$ rats, NS) (Fig. 3). Also, the time course of the effect induced by m-CPP was not different in 6-OHDA-treated rats than in rats with a sham lesion (data not shown).

The histological analysis did not reveal differences in subthalamic nucleus injection sites between sham- and 6-OHDA-treated rats. Indeed, the majority (six of eight for both sham- and 6-OHDA-treated rats) of tracks left by cannulas were located in the central part of the subthalamic nucleus (corresponding to plates 35–36 with respect to Paxinos and Watson, 1986). Three tracks were rostrolateral, whereas one was extremely caudal (in a 6-OHDA-treated rat). As noted previously (Eberle-Wang et al., 1996), implantations localized outside the subthalamic nucleus (removed from the statistical analysis of the data) corresponded to animals that did not develop oral movements after subthalamic injection of m-CPP (data not shown).

**Effect of m-CPP on Fos expression in the basal ganglia of rats with sham and 6-OHDA lesions**

**Striatum**

As reported previously for the indirect serotonergic agonist fenfluramine (Rouillard et al., 1996), immunoreactivity for Fos was heterogeneous in the striatum after injections of saline or m-CPP, with the medial striatum containing more labeled cells than the lateral striatum. Therefore, the density of Fos-positive nuclei was analyzed in four quadrants delimiting the dorsolateral, ventrolateral, dorsomedial, and ventromedial striatum (Rouillard et al., 1996; see Materials and Methods).

In the dorsomedial striatum, the number of Fos-immunoreactive nuclei (51.7 ± 14.3 cells/mm$^2$ on the left side, mean ± SEM, $n = 7$ sham-lesioned and vehicle-injected rats) increased to 518 ± 74 cells/mm$^2$ after m-CPP administration ($n = 8$) (Fig. 4). The immunoreactive neurons were organized in clusters of irregular shape and size. The density of Fos-immunoreactive cells after m-CPP administration was strongly reduced (~80%, $n = 6$) by a lesion of nigrostriatal dopaminergic neurons on the same side (two-way ANOVA, treatment × pretreatment, $F_{(1,23)} = 16.4, p < 0.0005$ (Figs. 4, 5A–C). The lesion of dopaminergic neurons by itself did not significantly modify the control levels of Fos (76 ± 14.8, Scheffe’s test, $n = 6$). Moreover, on the intact side, the ability of m-CPP to induce Fos immunoreactivity in the dorsomedial striatum (474 ± 78 vs 51 ± 7.2 cells/mm$^2$ in sham-lesioned animals receiving m-CPP and saline, respectively, $n = 8–7$) was not significantly modified in 6-OHDA-lesioned rats (421 ± 98

**Role of subthalamic neurons in the increase in m-CPP-induced oral movements in rats with a dopaminergic lesion**

The effect of a unilateral injection of m-CPP (0, 0.2, 0.5, and 1 μg) into the subthalamic nucleus on oral movements in sham- and
Similar enhancement of m-Fos expression (89 ± 6 vs saline, 2.6 ± 0.8 and 2.4 ± 0.4 immunoreactive cells/mm² in left and right sides, respectively) was not modified by the lesion of DA neurons (two-way ANOVA, treatment × pretreatment, F(1,23) = 0.03, NS, and F(1,23) = 0.005, NS, respectively, n = 6–8).

Figure 4. Quantitative analysis of the density of Fos-like immunoreactive cells in the dorsal lateral (DL), dorsomedial (DM), ventrolateral (VL), and ventromedial (VM) quadrants of the striatum after systemic administration of m-CPP (1 mg/kg, i.p.) in rats with sham- and 6-OHDA-induced lesions. The data are expressed as the mean ± SEM of Fos-like immunoreactive cells per square millimeter on the side of the lesion (white bars) and the contralateral side (black bars) in each experimental group. s/v, Sham/vehicle; s/C, sham/m-CPP; 6/v, 6-OHDA/vehicle; 6/C, 6-OHDA/m-CPP (n = 6–8 animals per group). Experiments were performed 4.5–5.5 weeks after the injection of 6-OHDA or its vehicle in the left substantia nigra. The nigrostriatal lesion decreased the number of Fos-like immunoreactive cells after m-CPP administration on the side of the lesion only in the dorsomedial and ventromedial striatum (two-way ANOVA; see Results). *p < 0.05, **p < 0.01, and ***p < 0.001 compared with saline-treated rats with a sham-lesion; +p < 0.05, +p < 0.01, and +++p < 0.001 compared with saline-treated rats with a 6-OHDA lesion; #p < 0.001 compared with m-CPP-treated rats with a sham-lesion (Scheffe’s test).

cells/mm², mean ± SEM, n = 6) (two-way ANOVA, treatment × pretreatment, F(1,23) = 0.63, NS, n = 6–8).

A similar pattern of response to m-CPP administration was observed in the ventromedial striatum. Indeed, m-CPP induced an increase of Fos immunoreactivity (300 ± 40 cells/mm²; n = 8), and this effect was significantly reduced (−50%, n = 5) on the side of the lesion in dopamine-depleted rats (two-way ANOVA, treatment × pretreatment, F(1,23) = 5.3, p < 0.05, n = 5–8). A similar enhancement of m-CPP-induced Fos expression was seen in the ventromedial striatum on the side contralateral to the lesion and was not affected by the lesion of dopaminergic neurons (two-way ANOVA, treatment × pretreatment, F(1,23) = 0.002, NS, n = 5–8).

In the left dorsolateral striatum, m-CPP significantly enhanced Fos expression (89 ± 18 vs 4.3 ± 1.2 cells/mm² in sham-lesioned rats treated with m-CPP and saline, respectively; n = 7–8), an effect that was not modified by the lesion of DA neurons (two-way ANOVA, treatment × pretreatment, F(1,23) = 1.5, NS, n = 6–8). Similar results were observed on the side contralateral to the lesion (two-way ANOVA, treatment × pretreatment, F(1,23) = 0.9, NS). Similarly, the increase in Fos immunoreactivity induced by m-CPP in the ventrolateral striatum of rats with a sham lesion (m-CPP, 71 ± 14 and 53 ± 19 immunoreactive cells/mm² vs saline, 2.6 ± 0.8 and 2.4 ± 0.4 immunoreactive cells/mm² in left and right sides, respectively) was not modified by the lesion of DA neurons (two-way ANOVA, treatment × pretreatment, F(1,23) = 0.03, NS, and F(1,23) = 0.005, NS, respectively, n = 6–8).

Globus pallidus

Very few Fos-immunoreactive cells were found in the globus pallidus (equivalent to the external pallidum of primates) of saline-treated rats with sham lesions (n = 7) (Fig. 6). Moreover, despite a trend to increase, m-CPP did not significantly modify Fos expression (Scheffe’s test). 6-OHDA-induced lesion did not affect this outcome (two-way ANOVA, treatment × pretreatment, F(1,22) = 0.013, NS, n = 6–7). The lesion of dopaminergic neurons by itself did not significantly modify basal Fos immunoreactivity (Scheffe’s test). Also, no significant difference was observed on the intact side after m-CPP injection in rats with or without a lesion of dopaminergic neurons (two-way ANOVA, treatment × pretreatment, F(1,22) = 0.9, NS, n = 6–7).

Subthalamus nucleus

An average of 19 ± 7 and 20 ± 12 labeled cells/mm² (mean ± SEM, n = 7) was observed in the left and right subthalamic nucleus, respectively, of animals with sham lesions and treated with saline. The dopaminergic lesion by itself did not significantly modify Fos immunoreactivity (Scheffe’s test, n = 6). m-CPP significantly increased Fos expression in the subthalamic nucleus on both sides in rats with sham lesions (68 ± 5 and 68 ± 10 in the left and right sides, p < 0.01 and p < 0.05, respectively, Scheffe’s test after one-way ANOVA, n = 8) (Fig. 6). This effect was not affected by the lesion of dopaminergic neurons regardless of the side considered (two-way ANOVA, treatment × pretreatment, F(1,23) = 0.03, NS, and F(1,23) = 1.2, NS, in the left and right side, respectively).

Entopeduncular nucleus

Despite a trend to increase the number of Fos-positive cells (9.8 ± 2.8 vs 3.4 ± 1.2 in m-CPP- and saline-treated rats, respectively, n = 8–7) (Fig. 6), m-CPP did not significantly modify basal Fos expression in the left entopeduncular nucleus in rats with sham lesions (Scheffe’s test). However, m-CPP markedly increased Fos-positive cells in rats with 6-OHDA lesions (41 ± 9.7 immunoreactive cells/mm²; n = 6) (two-way ANOVA, treatment × pretreatment, F(1,23) = 8.5, p < 0.01). Immunoreactive cells were mainly localized in the middle of the rostrocaudal extent of the region and tended to occupy the lateral part of the entopeduncular nucleus. The lesion by itself did not significantly affect basal Fos expression (7.4 ± 1.4, Scheffe’s test, n = 6). The slight increase in Fos immunoreactivity elicited by m-CPP in sham-lesioned rats reached significance on the side contralateral to the lesion (3.16 ± 1.2 vs 14.1 ± 2.6, p < 0.05, Scheffe’s test, n = 7–8) (Fig. 6) but not in lesioned side (4.5 ± 1.2 vs 10.4 ± 2.3, NS, n = 7–8), and the lesion did not significantly alter m-CPP effects on that side (two-way ANOVA, treatment × pretreatment, F(1,23) = 1.98, NS, n = 6–8).

Substantia nigra

As reported previously (Whirtshafter and Asin, 1995; Sgambato et al., 1997), very few Fos-immunoreactive cells were found along the rostrocaudal extent of the substantia nigra pars reticulata in...
saline-treated rats with a sham lesion. The moderate effects of m-CPP on Fos immunoreactivity did not reach significance (Scheffe’s test) (Fig. 6) and were not affected by the 6-OHDA lesion (two-way ANOVA, treatment × pretreatment, \( F_{(1, 24)} = 0.057 \), and \( F_{(1, 24)} = 0.876, n = 6–8 \), NS, on the left and right sides, respectively).

**DISCUSSION**

The results of this study reveal that the unilateral destruction of nigrostriatal DA neurons in adult rats alters *in vivo* responses to a peripheral administration of the 5-HT agonist m-CPP in the basal ganglia.

**Increased m-CPP-induced oral dyskinesia after nigrostriatal lesions**

As reported previously, peripheral administration of m-CPP induced an increase in oral movements (Stewart et al., 1989; Gong et al., 1992; Eberle-Wang et al., 1996). Based on previous pharmacological studies, the dose of 1 mg/kg m-CPP used in this study induces almost half of the maximal effect of m-CPP on oral movements (Gong et al., 1992; Eberle-Wang et al., 1996). A common property of 5-HT antagonists that reduce this effect is the ability to block 5-HT \(_{2C}\) but not 5-HT \(_{2A}\) or 5-HT \(_{1B}\) receptors (Gong et al., 1992; Eberle-Wang et al., 1996). In addition, 5-HT agonists at 5-HT \(_{1A}\) or/and 5-HT \(_{1B}\) receptors do not induce oral movements (Stewart et al., 1989; Gong et al., 1992). Together, these data indicate that oral movements elicited by m-CPP are likely mediated by 5-HT \(_{2C}\) receptors.

The ability of m-CPP to induce oral movements was dramatically enhanced by a unilateral lesion of nigral dopaminergic neurons. This observation extends previous evidence that chronic impairment of nigrostriatal DA transmission facilitates m-CPP-induced oral movements. Indeed, bilateral lesions of dopaminergic
m-CPP-induced Fos expression in the striatum

Our finding that m-CPP (1 mg/kg, i.p.) enhances Fos expression in the striatum agrees with evidence that m-CPP modulates striatal cells activity (El Mansari et al., 1994) and with previous data showing an increase in the number of Fos-immunoreactive striatal cells after higher doses (5 mg/kg) of the same drug (Cook and Wirtshafter, 1995). The 5-HT1B/2C agonists m-trifluoromethylphenylpiperazine and RU-24969, the 5-HT2A/2C agonist 2,5-dimethoxy-4-iodoamphetamine or the 5-HT releasers fenfluramine and p-chloroamphetamine have also been shown to enhance the number of Fos-immunoreactive cells in the striatum (Leslie et al., 1993; Moorman and Leslie, 1996; Rouillard et al., 1996; Cook and Whirtshafter, 1998).

Interestingly, striatal Fos expression induced by m-CPP was reduced by the lesion of nigrostriatal DA neurons in the dorsomedial and ventromedial quadrants. The smaller effect of dopaminergic lesion observed in the ventromedial compared with the dorsomedial region could be attributable to the sparing of the DA input from the ventral tegmental area (Gerfen et al., 1987) in our experimental conditions. Fenfluramine-induced increase in Fos-immunoreactive cells was also reduced in the striatum by a lesion of DA neurons and by the DA-D2 antagonist SCH-23390 (Rouillard et al., 1996). In the case of fenfluramine, it is possible that the lesion exerted its effect by preventing an increase in striatal DA release (De Deurwaerdère et al., 1995). However, such mechanism is unlikely to play a role after m-CPP injections because this drug does not affect striatal DA release at the dose used in this study (Di Giovanni et al., 2000).

Our results and that of these previous studies clearly indicate that the ability of m-CPP to induce Fos in the striatum is, at least in part, dependent on the tonic control exerted by DA on striatal neurons. Whereas 5-HT2C receptor stimulation has been clearly shown to account for oral movements induced by m-CPP in rats with or without neonatal dopaminergic lesions (Gong and Kostrzewa, 1992; Eberle-Wang et al., 1996), the ability of 5 mg/kg m-CPP to enhance the number of Fos-immunoreactive cells in the striatum was not reduced by the 5-HT2A/2C antagonist ritalinic acid (Cook and Whirtshafter, 1995). Despite the high dose used by these authors, likely recruiting several mechanisms (Kahn and Wetzler, 1991; Eriksson et al., 1999), it is possible that Fos expression after m-CPP administration is not solely mediated by 5-HT2C receptors. In the absence of selective 5-HT2C agonists and antagonists, extensive pharmacological characterizations will be necessary to identify the 5-HT receptors involved in this effect. Whatever the receptor(s) involved, the altered effect of m-CPP in dopamine-depleted rats could be attributable to a change either in the receptors themselves or in signal transduction mechanisms linking the receptor to Fos expression. Of note, striatal 5-HT2C receptor mRNA levels were not modified in adult rats with a lesion of the nigrostriatal dopaminergic neurons (Numan et al., 1995).

Alterations in m-CPP-induced Fos expression in the entopeduncular nucleus after dopaminergic lesions

The only other region of the basal ganglia that showed a difference in m-CPP-induced Fos expression after nigrostriatal lesion is the entopeduncular nucleus. The mechanism of the marked increase in Fos induction observed in this region after nigrostriatal lesions is unclear. In primates, dopaminergic lesions increase the firing rate of neurons of the internal pallidum, a region equivalent to the entopeduncular nucleus, and modify their firing pattern (DeLong, 1990; Brotchie et al., 1991; Borau et al., 1998).
Similar cellular changes in rats could enhance the response to the stimulation of 5-HT$_{2C}$ receptors that are present in this region (Pazos et al., 1985; Eberle-Wang et al., 1997). The effects of 5-HT$_{2C}$ agonists on entopeduncular neurons are, however, not known. Striatal GABAergic neurons that project to the entopeduncular nucleus could also participate in this effect. Indeed, previous data showed a reduction of fenfluramine-induced Fos immunoreactivity in these neurons by D1 antagonists (Rouillard et al., 1996). This suggests that dopamine may facilitate a serotonergic regulation of these neurons. Thus, in the absence of dopamine, m-CPP would be unable to regulate (presumably activate) this inhibitory input to the entopeduncular nucleus, unmasking a direct effect of m-CPP on Fos expression in this region.

Interestingly, a similar increase in Fos expression was not observed in the substantia nigra pars reticulata. A difference in distribution of 5-HT$_{2C}$ receptors between entopeduncular nucleus and substantia nigra pars reticulata could account for the differential effects of m-CPP in these two regions. Indeed, although functional 5-HT$_{2C}$ receptors have been also found in the substantia nigra pars reticulata (Rick et al., 1995; Fox et al., 1998), only a subpopulation of neurons in its caudal region express 5-HT$_{2C}$ receptor mRNA in contrast to virtually all neurons of the entopeduncular nucleus (Eberle-Wang et al., 1997). A differential distribution of receptors is also likely to account for the lack of robust Fos induction in the globus pallidus after m-CPP injections in rats with or without lesions. Indeed, neurons of the globus pallidus do not express 5-HT$_{2C}$ receptor mRNA, and the density of 5-HT$_{2C}$ receptor binding sites in this region is very low (Pazos et al., 1985; Eberle-Wang et al., 1997; Pasqualetti et al., 1999). Together, the data reveal that m-CPP increases Fos expression preferentially in basal ganglia subregions displaying the greatest density of 5-HT$_{2C}$ receptor.

**Functional implications**

It is unclear whether the regionally specific changes in m-CPP-induced Fos expression observed after nigrostriatal lesion are, in any way, related to the enhanced behavioral response observed in the same conditions. However, it is of interest to note that the two regions of the basal ganglia with lesion-induced changes in Fos expression after dopaminergic lesions have also been implicated in oral dyskinesia. The ventral striatum is involved in the control of oral activity (Salamone et al., 1990). A role for the striatum is supported by data showing that oral movements induced by a local injection of m-CPP into the ventral striatum are enhanced in rats treated with 6-OHDA as neonate (Pleck et al., 1995). A role of the entopeduncular nucleus in dyskinesia is suggested by the antidysonic effect of lesions or high-frequency stimulation of its equivalent, the posteroverentral region of the internal pallidum (Dagali et al., 1995; Sutton et al., 1995; Lang et al., 1999).

Hyperkinetic side effects remain a major complication of long-term treatments with neuroleptics or 1-DOPA in schizophrenia or Parkinson’s disease, respectively (Tarsy and Baldessarini, 1984; Chase et al., 1994). The results of the present study indicate that a lesion of dopaminergic neurons similar to that causing Parkinson’s disease alters behavioral and cellular responses elicited by stimulation of 5-HT receptors. Dopaminergic agonists and 1-DOPA can increase the release of 5-HT in several brain regions (Ng et al., 1972; Ferré et al., 1994; Thorre et al., 1998). Therefore, an excess of serotonergic transmission, together with the changes in functional responses to serotonin induced by the dopaminergic lesion, may be involved in the development of dyskinesia after dopamine replacement therapy. This is supported by clinical evidence that 5-HT$_{2C}$ antagonists can be useful to treat the complications of antiparkinsonian therapy (Ikeguchi and Kuroda, 1995; Pact and Giduz, 1999).

**REFERENCES**


Moorman JM, Leslie RA (1996) The neostriatal mosaic. II. Patch-and matrix-directed mesostriatal dopaminergic and non-

Gong L, Kostrzewa RM (1992) Supersensitized oral response to a sere-
tonin agonist in neonatal 6-OHDA-treated rats. Pharmacol Biochem
Behav 41:621–623.

Gong L, Kostrzewa RM, Fuller RW, Perry KW (1992) Supersensitization
of oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is

Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psy-
chosis induced by antiaparkinsonian drugs. Eur Arch Psychiatry Clin
Neurosci 244:320–324.

Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of

Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural ad-
aptations to ontogenic loss dopamine neurons in rat brain. J Neuro-

Lang AE, Duff J, Saint-Cyr JA, Trepanier L, Gross RE, Lombardi W,

Leslie RA, Moorman JM, Coulson A, Grahame-Smith DG (1993)
Serotonin2/1C receptor activation causes a localized expression of
the immediate-early gene c-fos in rat brain: evidence for involve-
m ent of dorsal raphe nucleus projection fibres. Neuroscience
53:457–463.

Mehta A, Thermos K, Chesselet M-F (2000) Increased behavioral re-
sponse to dopaminergic stimulation of the subthalamic nucleus after
nigrostriatal lesions. Synapse, in press.

ment of serotonin in clinical features of Parkinson’s disease and com-

Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin

Moorman JM, Leslie RA (1996) m-Chloroamphetamine induces c-fos in
rat brain: a study of serotonin2A/2C receptor function. Neuroscience
72:129–139.

Ng LKY, Chase TN, Colburn RW, Kopin IJ (1972) t-DOPA in parkin-

Increased expression of 5-HT2 receptor mRNA in rat striatum follow-
ing 6-OHDA lesions of the adult nigrostriatal pathway. Mol Brain Res
29:391–396.


stimulation of subthalamic nucleus elicits oral dyskinesia in rats. Exp

Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I
(1999) Distribution and cellular localization of the serotonin type 2C


Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic
mapping of serotonin receptors in the rat brain. II. Serotonin-2 recep-

activity responses to intrastriatal SKF 38393 and m-CCP are attenu-
ated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats.
Psychopharmacology 119:466-473.

nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for
a direct action mediated by 5-hydroxytryptamine2C receptors.
Neuroscience 69:903-913.

Roth BL, Ciaramello RD, Meltzer HY (1992) Binding of typical and
atypical antipsychotic agents to transiently expressed 5-HTIC recep-

Rouillard C, Bovetto S, Gervais J, Richard D (1996) Fenfluramine-
induced activation of the immediate-early gene c-fos in the striatum:
possible interaction between serotonin and dopamine. Mol Brain Res

Salamone JD, Johnson CJ, McCullough LD, Steinpreis RE (1990) Lat-
eral striatal cholinergic mechanisms involved in oral motor activities in
the rat. Psychopharmacology 85:71–79.

(5-HT) 5-HT2C receptor function in caudate. 28th Annual Meeting of
Society for Neuroscience, Los Angeles, CA, November.

Sgambato V, Abo V, Rogard M, Besson MJ, Deniau JM (1997) Effect of
electrical stimulation of the cerebral cortex on the expression of the Fos
protein in the basal ganglia. Neuroscience 81:93–112.

chewing behavior in rats by 5-HT agonists drugs. Eur J Pharmacol

Sutton JP, Coudwell L, Lew MF, Mallory L, Grafton S, DeGiorgio C,
Welsh M, Apuzzo MLJ, Ahmadi J, Waters CH (1995) Ventroposte-
rior medial pallidotomy in patients with advanced Parkinson’s disease.
Neurosurgery 36:1112–1117.

35:605–623.

nergic regulation of serotonin release in the substantia nigra of the

Trent F, Tepper JM (1991) Dorsal raphe stimulation modifies striatal-
evoked antidromic invasion of nigral dopaminergic neurons in vivo. Exp
Brain Res 84:620–630.

Wirthschaftner D, Asin KE (1995) Dopamine antagonists induce fos-like
immunoreactivity in the substantia nigra and entopeduncular nucleus